← All trials
NCT06094010
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2023
- Primary completion
- May 11, 2027
- Completion date
- Jun 30, 2027
- First posted
- Oct 23, 2023
- Last posted
- Dec 8, 2023
- Enrollment
- 600
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.